Literature DB >> 14509512

Preservation of form and function during management of cancer of the larynx and hypopharynx.

Jean Louis Lefebvre1, Eric Lartigau.   

Abstract

The treatment of laryngeal and hypopharyngeal cancer has seen notable changes during the twentieth century. Intensive surgical research has allowed laryngologists to deal with almost any local extension and to propose an appropriate surgical procedure for each case. This surgery is able to control the disease in most patients locally but is limited in its indications (resectable diseases and operable patients). On the other hand, radiotherapy has been impressively improved (dosimetry, definition of target volume) and has become an indisputable alternative to surgery. The two approaches are comparable in terms of local control and functional results when dealing with early disease. For advanced disease, however, the debate is open between surgery, which is more efficient but mutilating, and radiotherapy, which can preserve the larynx in many instances even though it requires sometimes mutilating surgery for salvage. The appearance of platinum-based chemotherapy has updated this discussion. To date, most of the randomized comparisons of mutilating/nonmutilating approaches have been with induction chemotherapy followed by irradiation if there has been a good clinical response to the chemotherapy. There are other options as well that deserve evaluation (e.g., radiotherapy with altered fractionation or with concurrent chemotherapy), although surgery still seems to be indicated in certain cases. Finally, efforts should be made to select patients properly (based on tumor characteristics, clinical aspects, imaging, and biology) for the various strategies with the primary goal of curing the patient and secondarily to preserve laryngeal form and function when possible.

Entities:  

Mesh:

Year:  2003        PMID: 14509512     DOI: 10.1007/s00268-003-7106-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  22 in total

1.  Definitive radiotherapy for 114 cases of T3N0 glottic carcinoma: influence of dose-volume parameters on outcome.

Authors:  J P Wylie; M Sen; R Swindell; A J Sykes; W T Farrington; N J Slevin
Journal:  Radiother Oncol       Date:  1999-10       Impact factor: 6.280

2.  Stage T3 squamous cell carcinoma of the glottic larynx: a comparison of laryngectomy and irradiation.

Authors:  W M Mendenhall; J T Parsons; S P Stringer; N J Cassisi; R R Million
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  Continuous, hyperfractionated, accelerated radiotherapy (CHART): an interim report upon late morbidity.

Authors:  S Dische; M I Saunders
Journal:  Radiother Oncol       Date:  1989-09       Impact factor: 6.280

4.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

Authors:  K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

5.  A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.

Authors:  S Dische; M Saunders; A Barrett; A Harvey; D Gibson; M Parmar
Journal:  Radiother Oncol       Date:  1997-08       Impact factor: 6.280

6.  Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer.

Authors:  D H Kraus; D G Pfister; L B Harrison; J P Shah; R H Spiro; J G Armstrong; D E Fass; M Zelefsky; S P Schantz; M H Weiss
Journal:  Otolaryngol Head Neck Surg       Date:  1994-07       Impact factor: 3.497

7.  A comparison of the late radiation changes after three schedules of radiotherapy.

Authors:  E Lartigau; M I Saunders; S Dische; M F Warburton; C Des Rochers
Journal:  Radiother Oncol       Date:  1991-03       Impact factor: 6.280

8.  Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.

Authors:  M Merlano; V Vitale; R Rosso; M Benasso; R Corvò; M Cavallari; G Sanguineti; A Bacigalupo; F Badellino; G Margarino
Journal:  N Engl J Med       Date:  1992-10-15       Impact factor: 91.245

9.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

10.  Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx.

Authors:  J Overgaard; M Hjelm-Hansen; L V Johansen; A P Andersen
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

View more
  2 in total

1.  Functional analysis of swallowing outcomes after supracricoid partial laryngectomy.

Authors:  Jan S Lewin; Katherine A Hutcheson; Denise A Barringer; Annette H May; Dianna B Roberts; F Christopher Holsinger; Eduardo M Diaz
Journal:  Head Neck       Date:  2008-05       Impact factor: 3.147

2.  Predictors of thyroid gland involvement in hypopharyngeal squamous cell carcinoma.

Authors:  Jae Won Chang; Yoon Woo Koh; Woong Youn Chung; Soon Won Hong; Eun Chang Choi
Journal:  Yonsei Med J       Date:  2015-05       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.